<DOC>
	<DOCNO>NCT01511263</DOCNO>
	<brief_summary>In proportion patient AL amyloidosis improvement cardiac function despite hematologic response treatment . The aim study ass whether treatment EGCG increase rate cardiac response patient AL amyloidosis complete chemotherapy .</brief_summary>
	<brief_title>Epigallocatechingallate ( EGCG ) Cardiac AL Amyloidosis</brief_title>
	<detailed_description>This phase II open-label randomize trial . Patients AL amyloidosis cardiac involvement achieve least partial hematologic response chemotherapy randomize receive standard supportive therapy ( SST ) SST plus Epigallocatechin gallate ( EGCG ) . After give write informed consent , patient evaluate eligibility . Briefly , subject biopsy-proven diagnosis AL amyloidosis achieve least partial response chemotherapy , plan receive chemotherapy significant cardiac dysfunction consider eligible . The patient stratify accord quality hematologic response severity cardiac involvement . Following stratification , patient randomize receive SST SST plus EGCG . The study comprise 3 period : screening ( include stratification randomization ) , treatment ( evaluation response every 2 month ) follow end-of-treatment evaluation follow-up . Therapy continue 1 year . After treatment patient follow 3 year .</detailed_description>
	<mesh_term>Amyloidosis</mesh_term>
	<mesh_term>Amiodarone</mesh_term>
	<mesh_term>Anti-Arrhythmia Agents</mesh_term>
	<mesh_term>Diuretics</mesh_term>
	<mesh_term>Epigallocatechin gallate</mesh_term>
	<criteria>Diagnosis AL amyloidosis . Age ≥18 year . The patient must treat AL amyloidosis attain hematologic response . Evidence cardiac involvement echocardiography ( mean leave ventricular wall thickness &gt; 12 mm absence cause ) . NTproBNP ≥650 ng/L NonAL ( e.g . familial , senile ) amyloidosis . Concomitant nonamyloid relate clinically significant cardiac disease . Need chemotherapy AL amyloidosis . Estimated glomerular filtration rate ( eGFR ) &lt; 30 mL/min per 1.73 m2 . Uncontrolled infection . Inability give inform consent . Previous ongoing psychiatric illness ( exclude reactive depression ) . Pregnant nursing woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Epigallocatechin gallate</keyword>
	<keyword>AL amyloidosis</keyword>
</DOC>